Rchr
J-GLOBAL ID:201601014636233760
Update date: Mar. 18, 2024
Matsushita Hirokazu
マツシタ ヒロカズ | Matsushita Hirokazu
Affiliation and department:
Job title:
Chief
Homepage URL (1):
https://kaken.nii.ac.jp/d/r/80597782.ja.html
Research field (5):
Digestive surgery
, Respiratory surgery
, Cardiovascular surgery
, Urology
, Tumor diagnostics and therapeutics
Research keywords (30):
変異ペプチド
, ミスセンス変異
, 次世代シーケンス
, 固有抗原
, 全エクソームシーケンス
, 全RNAシーケンス
, 腎がん
, MHC class I 結合予測法
, γδT細胞
, エクソームシーケンス
, 胃がん
, ワクチン治療
, 化学療法
, 膵癌
, 免疫反応
, 腎細胞癌
, 免疫細胞治療
, メッセンジャーRNA(mRNA)
, 肺癌
, 肺がん
, CAR
, Chimeric Antigen Receptor(CAR)
, 細胞傷害性T細胞
, 樹状細胞療法
, 有害事象
, HSP105
, MHC binding prediction法
, 免疫学的評価
, メッセンジャーRNA
, 樹状細胞ワクチン治療
Research theme for competitive and other funds (28):
- 2022 - 2025 The determination of T-cell fate by different tumor antigens and prevention of post-operative recurrence of lung cancer
- 2022 - 2025 Identification of resistant mechanisms of tumor cells against CAR-T cell-mediated cytotoxicity
- 2021 - 2025 Ready-tp-Use RNA-drug discovery for the acceleration of personalized cancer vaccine
- 2021 - 2025 簡易モニタリングのための好酸球を用いた頭頸部がん免疫治療バイオマーカーの開発
- 2021 - 2023 免疫一細胞データ解析による改変型T細胞受容体デザイン技術の開発
- 2020 - 2023 個別化がんワクチン療法に向けた統合プロテオミクスによる新規がん抗原同定法の開発
- 2020 - 2023 末梢血中循環腫瘍細胞を用いた非小細胞肺癌への化学療法による免疫原性細胞死の解析
- 2020 - 2023 In-depth surfaceome analysis of PDX models to develop innovative personalized therapies in pancreatic cancer
- 2019 - 2023 卵巣癌の個別化治療を目指した免疫プロファイルに基づく包括的バイオマーカーの開発
- 2019 - 2022 Specific immune responses against tumor antigens in long term survivors of cancer
- 2017 - 2020 Analysis of intratumoral immune response in head and neck cancer for optimal combination immunotherapy
- 2017 - 2020 Comprehensive profiling of tumor immune microenvironment for effective personalized lung cancer vaccine
- 2017 - 2020 Analysis of intratumoral immune response in gastric and esophageal cancer for optimal combination immunotherapy
- 2016 - 2020 Integrative analysis of lineage-survival signaling in lung adenocarcinoma
- 2016 - 2019 Neoantigen and local immune profile in ovarian clear cell carcinoma
- 2016 - 2019 Development of cancer immunotherapy targeting mutation-derived neoantigens
- 2016 - 2019 Novel cancer immunotherapy targeting neoantigens in combination with epigenetics and immune modulation
- 2015 - 2019 Analysis of intra-tumor immune response toward development of autologous gamma-delta T-cell transfer therapy in patients with advanced urothelial carcinoma
- 2015 - 2018 Development of personalized lung cancer vaccine targeting neoantigens
- 2015 - 2017 Detection of neoantigens by gene-engineered T cells
- 2014 - 2017 Identification of neoantigens and development of a novel personalized lung cancer treatment targeting passenger mutations
- 2013 - 2016 DC-based vaccination combined with interferon for metastatic renal cell carcinoma
- 2013 - 2016 Mutanome analyses by next generation sequencing and individualized cancer vaccine development in gastric cancer
- 2013 - 2016 Identification of unique antigens by next generation sequencing and development of individualized cancer immunotherapy in clear cell renal cell carcinoma
- 2012 - 2016 Chimeric antigen receptor gamma delta T cell immunotherapy for the treatment of malignant mesothelioma
- 2012 - 2015 Development of cancer vaccine therapy targeting individual genetic mutations identified by next generation sequencing
- 2012 - 2015 Reverse Translational Research for Understanding immune response in the Tumor and Identification of Biomarkers
- 2011 - 2013 Vaccination therapy combined with chemotherapy for recurrent pancreatic cancer patients
Show all
Papers (83):
-
Eiichi Sasaki, Katsuhiro Masago, Hirokazu Matsushita. Are Solitary Fibrous Tumors of the Pancreas the Same Tumor as Pancreatic Hamartomas?. The American journal of surgical pathology. 2024
-
Eiichi Sasaki, Hirokazu Matsushita, Katsuhiro Masago, Nobuhiro Hanai. RAS Mutations in Esophageal Squamous Papilloma. International journal of surgical pathology. 2024. 10668969231216987-10668969231216987
-
Hiromasa Ishihara, Daisuke Nishikawa, Daisuke Muraoka, Katsuhiro Masago, Shintaro Beppu, Hoshino Terada, Hirokazu Matsushita, Nobuhiro Hanai. Changes in serum DAMPs and cytokines/chemokines during near-infrared photoimmunotherapy for patients with head and neck cancer. Cancer medicine. 2023
-
Teppei Yamaguchi, Katsuhiro Masago, Eiichi Sasaki, Hiroaki Kuroda, Hirokazu Matsushita, Yoshitsugu Horio. EML4-ALK Variant 3a/b as a mechanism of osimertinib resistance in a patient with EGFR L858R positive NSCLC. Cancer genetics. 2023. 280-281. 13-16
-
Yoshitsugu Horio, Hiroaki Kuroda, Katsuhiro Masago, Hirokazu Matsushita, Eiichi Sasaki, Yutaka Fujiwara. Current diagnosis and treatment of salivary gland-type tumors of the lung. Japanese journal of clinical oncology. 2023
more...
MISC (61):
-
長谷川 幸清, 松下 博和, 織田 克利, 山本 尚吾, 浅田 佳代, 西島 明, 唐崎 隆弘, 池田 悠至, 藤原 恵一, 油谷 浩幸, et al. 卵巣漿液性癌におけるDNA相同組換え修復、ネオアンチゲンおよび局所免疫の関連(A subgroup with a T-cell inflamed phenotype in homologous recombination proficient high-grade serous ovarian carcinoma). 日本癌学会総会記事. 2018. 77回. 1149-1149
-
根城 尭英, 松下 博和, 野村 昌志, 田中 將太, 永江 玄太, 成田 善孝, 永根 基雄, 西川 亮, 植木 敬介, 油谷 浩幸, et al. 神経膠腫におけるネオアンチゲンと免疫微小環境の経時変化に関するマルチオミクス解析(Integrated Omics Analysis on Temporal Changes of Neoantigen and Tumor Microenvironment in Primary and Recurrent Gliomas). 日本癌学会総会記事. 2018. 77回. 1778-1778
-
松下 博和, 垣見 和宏. ネオ抗原同定と免疫治療への応用 次世代シーケンサーを活用したネオアンチゲンと抗腫瘍免疫応答の解析. 日本がん免疫学会総会プログラム・抄録集. 2018. 22回. 45-45
-
根城 尭英, 松下 博和, 唐崎 隆弘, 野村 昌志, 永江 玄太, 高柳 俊作, 田中 將太, 成田 善孝, 永根 基雄, 西川 亮, et al. 神経膠腫におけるネオアンチゲンと免疫微小環境の経時変化に関するマルチオミクス解析. 日本がん免疫学会総会プログラム・抄録集. 2018. 22回. 84-84
-
長岡 孝治, 唐崎 隆弘, 長山 和弘, 中島 淳, 松下 博和, 垣見 和宏. 免疫チェックポイント阻害剤治療によるイムノグラムの変動. 日本がん免疫学会総会プログラム・抄録集. 2018. 22回. 87-87
more...
Work history (1):
- 2013 - The University of Tokyo
Return to Previous Page